Skip to main content
main-content

01.04.2011 | Review | Ausgabe 2/2011

International Ophthalmology 2/2011

Adalimumab (Humira): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

Zeitschrift:
International Ophthalmology > Ausgabe 2/2011
Autoren:
Piergiorgio Neri, Manuela Zucchi, Pia Allegri, Marta Lettieri, Cesare Mariotti, Alfonso Giovannini
Wichtige Hinweise
P. Neri and M. Zucchi contributed equally to this publication

Abstract

Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2011

International Ophthalmology 2/2011 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde